Content by aTen Therapeutics
IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen
| 1 min read
Page 1 of 1 - 1 Total Items
IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen
CURRENT ISSUE - September 2024
Transforming lab culture through effective communication and leadership